Clinical Trials | March 11, 2026
Roche reports Phase III persevERA breast cancer trial results
Giredestrant shows promise despite missing primary goal
Giredestrant shows promise despite missing primary goal
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Germany will be the first launch market
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
Subscribe To Our Newsletter & Stay Updated
